Respiratory syncytial virus - Immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral Infections: Part I

Journal of Pediatric Health Care

Volumn 11, Issue 6, 1997, Pages 284-291

  Sandritter, Tracy L ^a   Kraus, Donna M ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b M/C 886 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

HUMAN; INFANT; NEWBORN; PRESCHOOL CHILD; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VIRUS INFECTION;

CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0031263673     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0891-5245(97)90086-9     Document Type: Article

References (37)

1. American Academy of Pediatrics: Committee on Infectious Diseases, Committee on Fetus and Newborn. (1997). Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics, 99, 645-650.
2. American Academy of Pediatrics: Committee on Infectious Diseases. (1993). Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics, 92, 501-504.
3. Connolly, J.H., Field, C.M.B., Glasgow, J.F.T., Slattery, C.M., & MacLynn, D.M. (1969). A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncytial virus. Acta Paediatrica Scandinavica, 58, 116-120.
4. Ellenberg, S.S., Epstein, J.S., Fratantoni, J.C., Scott, D., & Zoon, K.C. (1994). A trial of RSV globulin in infants and young children: The PDA's view [Letter to the editor]. The New England Journal of Medicine, 331, 203-204.
5. Gardner, P.S., Turk, D.C., Aherne, W.A., Bird, T., Holdaway, M.D., & Court, S.D.M. (1967). Deaths associated with respiratory tract infection in childhood. The British Medical Journal, 4, 316-320.
6. Glezen, W.P., & Denny, F.W. (1973). Epidemiology of acute lower respiratory disease in children. The New England Journal of Medicine, 288, 498-505.
7. Glezen, W.P., Taber, L.H., Frank, A.L., & Kasel, J.A. (1986). Risk of primary infection and reinfection with respiratory syncytial virus. American Journal of Diseases of Children, 140, 543-546.
8. Groothuis, J.R., Gutierrez, K.M., & Lauer, B.A. (1988). Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics, 82, 199-203.
9. Groothuis, J.R., Hemming, V.G., Siber, G.R., & Top, F.H., Jr. (1994). A trial of RSV immune globulin in infants and young children [Letter to the editor]. The New England Journal of Medicine, 331, 204-205.
10. Groothuis, J.R., Levin, M.J., Rodriguez, W., Hall, C.B., Long, C.E., Kim, H.W., Lauer, B.A., Hemming, V.G., & the RSVIG study group. (1991). Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrobial Agents and Chemotherapy, 35, 1469-1473.
11. Groothuis, J.R., Simoes, E.A.F., Hemming, V.G., & the RSVIG study group. (1995). Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics, 95, 463-467.
12. Groothuis, J.R., Simoes, E.A.F., Levin, M.J., Hall, C.B., Long, C.E., Rodriguez, W.J., Arrobio, J., Meissner, H.C., Fulton, D.R., Welliver, R.C., Tristram, D.A., Siber, G.R., Prince, G.A., Van Raden, M., Hemming, V.G. & the RSVIG study group. (1993). Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The New England Journal of Medicine, 329, 1524-1530.
13. Hall, C.B. (1993). Respiratory syncytial virus: what we know now. Contemporary Pediatrics, 10, 92-110.
14. Hall, C.B., & Douglas, R.G., Jr. (1981). Modes of transmission of respiratory syncytial virus. The Journal of Pediatrics, 99, 100-102.
15. Hall, C.B., McBride, J.T., Walsh, E.E., Bell, D.M., Gala, C.L., Hildreth, S., Ten Eyck, L.G., & Hall, W.J. (1983). Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection: a randomized double-blind study. The New England Journal of Medicine, 308, 1443-1447.
16. Hall, C.B., & McCarthy, C.A. (1995). Respiratory syncytial virus. In G.L. Mandell, J.E. Bennett, & R. Dolin (Eds.), Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (pp. 1501-1519). New York, NY: Churchill Livingstone.
17. Hemming, V.G., Prince, G.A., Horswood, R.L., London, W.T., Murphy, B.R., Walsh, E.E., Fischer, G.W., Weisman, L.E., Baron, P.A., & Chanock, R.M. (1985). Studies of passive immunotherapy for infections of respiratory syncytial virus in the. respiratory tract of a primate model. The Journal of Infectious Diseases, 152, 1083-1087.
18. Hemming, V.G., Prince, G.A., Groothuis, J.R., & Siber, G.R. (1995). Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clinical Microbiology Reviews, 8, 22-33.
19. Henderson, F.W. (1996). Viral respiratory infections. In A.M. Rudolph, J.I. Hoffman, C.D. Rudolph (Eds.), Rudolph's Pediatrics (pp. 671-674). Stamford, CT: Appleton & Lange.
20. Hendry, R.M., Pierik, L.T., & McIntosh, K. (1989). Prevalence of respiratory syncytial virus subgroups over six consecutive outbreaks: 1981-1987. The Journal of Infectious Diseases, 160, 185-190.
21. Institute of Medicine: Committe on Issues and Priorities for New Vaccine Development. (1985). Prospects for immunizing against respiratory syncytial virus (appendix N). In New vaccine development: Establishing priorities. Volume 1: Diseases of importance in the United States (pp. 397-409). Washington, DC: National Academy Press.
22. Kim, H.W., Canchola, J.G., Brandt, C.D., Pyles, G., Chanock, R.M., Jensen, K., & Parrott, R.H. (1969). Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. American Journal of Epidemiology, 89, 422-434.
23. Levin, M.J. (1994). Treatment and prevention options for respiratory syncytial virus infections. The Journal of Pediatrics, 124, S22-S27.
24. MacDonald, N.E., Hall, C.B., Suffin, S.C., Alexson, C., Harris, P.J., & Manning, J. A. (1982). Respiratory syncytial viral infection in infants with congenital heart disease. The New England Journal of Medicine, 307, 397-400.
25. Meissner, H.C., Fulton, D.R., Groothuis, J.R., Geggel, R.L., Marx, G.R., Hemming, V.G., Hougen, T., & Snydman, D.R. (1993). Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrobial Agents and Chemotherapy, 37, 1655-1658.
26. Meissner, H.C., Welliver, R.C., Chartrand, S.A., Fulton, D.R., Rodriguez, W.J.A., & Groothuis, J.R. (1996). Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. The Pediatric Infectious Disease Journal, 15, 1059-1068.
27. Parrott, R.H., Kim, H.W., Arrobio, J.O., Hodes, D.S., Murphy, B.R., Brandt, C.D., Camargo, E., & Chanock, R.M. (1973). Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race, and sex. American Journal of Epidemiology, 98, 289-300.
28. PREVENT Study Group. (1997). Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics, 99, 93-99.
29. Prince, G.A., Horswood, R.L., & Chanock, R.M. (1985). Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. Journal of Virology, 55, 517-520.
30. Product information. (1996). RespiGam. Gaithersburg, MD: MedImmune, Inc.
31. Simoes, E.A.F., Sondheimer, H.M., Meissner, H.C., Welliver, R.C., Groothuis, J.R., & the RSVIG cardiac study group. (1996). Respiratory syncytial virus immunoglobulin as prophylaxis against respiratory syncytial virus in children with congenital heart disease [abstract]. Pediatric Research, 39, 113A.
32. Smith, D.W., Frankel, L.R., Mathers, L.H., Tang, A.T.S., Ariagno, R.L., & Prober, C.G, (1991). A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. The New England Journal of Medicine, 325, 24-29.
33. Taketomo, C.K., Hodding, J.H., & Kraus, D.M. (1997). Pediatric Dosage Handbook (4th ed.) (pp. 648-649). Hudson (Cleveland), OH: Lexi-Comp Inc.
34. Taylor, C.E., Morrow, S., Scott, M., Young, B., & Toms, G.L. (1989). Comparative virulence of respiratory syncytial virus subgroups A and B. The Lancet, 1, 777-778.
35. Update: Respiratory syncytial virus activity in the United States, 1995-1996 season. (1995). MMWR, 44, 900-902.
36. Wang, E.E.L., Law, B.J., Stephens, D., & other members of PICNIC. (1995). Pediatric Investigators Collaborative Network on Infections in Canada (PIC-NIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. The Journal of Pediatrics, 126, 212-219.
37. Wright, P.F., Belshe, R.B., Kim, H.W., Van Voris, L.P., & Chanock, R.M. (1982). Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infection and Immunity, 37, 397-400.